Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 603,791 |
|
|||||
| News | - | ||||||
| Day High | 6.575 | Low High |
|||||
| Day Low | 6.06 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Replimune Group Inc | REPL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.27 | 4.39% | 6.42 | 17:08:24 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.22 | 6.06 | 6.575 | 6.42 | 6.15 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,990 | 603,791 | $ 6.37 | $ 3,845,289 | - | 5.25 - 24.81 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:13:44 | 18 | $ 6.42 | USD |
Replimune Group Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 393.5M | 61.39M | - | 0 | -174.28M | -2.84 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Replimune News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical REPL Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.90 | 7.07 | 5.86 | 6.36 | 798,158 | -0.48 | -6.96% |
| 1 Month | 8.17 | 8.17 | 5.86 | 6.99 | 844,661 | -1.75 | -21.42% |
| 3 Months | 7.72 | 9.20 | 5.86 | 7.87 | 1,189,899 | -1.30 | -16.84% |
| 6 Months | 14.14 | 15.18 | 5.25 | 8.35 | 1,505,664 | -7.72 | -54.60% |
| 1 Year | 17.32 | 24.81 | 5.25 | 11.45 | 1,034,956 | -10.90 | -62.93% |
| 3 Years | 31.80 | 40.22 | 5.25 | 16.33 | 581,621 | -25.38 | -79.81% |
| 5 Years | 16.39 | 54.85 | 5.25 | 19.70 | 446,744 | -9.97 | -60.83% |
Replimune Description
| Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
